Seroatlas · Human Serome Atlas

LYPD3

Ly6/PLAUR domain-containing protein 3

Also known as: C4.4A, LYPD3_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: O95274
Gene: LYPD3
Ensembl: ENSG00000124466
Chromosome: 19
Canonical length: 346 aa
Protein class: Predicted membrane proteins
Subcellular location: Endoplasmic reticulum,Vesicles

OverviewNCBI Gene

Predicted to enable laminin binding activity. Involved in negative regulation of smooth muscle cell apoptotic process. Located in extracellular space. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

346 residues, UniProt reviewed canonical sequence.

>O95274|LYPD3
     1  MDPARKAGAQ AMIWTAGWLL LLLLRGGAQA LECYSCVQKA DDGCSPNKMK TVKCAPGVDV
    61  CTEAVGAVET IHGQFSLAVR GCGSGLPGKN DRGLDLHGLL AFIQLQQCAQ DRCNAKLNLT
   121  SRALDPAGNE SAYPPNGVEC YSCVGLSREA CQGTSPPVVS CYNASDHVYK GCFDGNVTLT
   181  AANVTVSLPV RGCVQDEFCT RDGVTGPGFT LSGSCCQGSR CNSDLRNKTY FSPRIPPLVR
   241  LPPPEPTTVA STTSVTTSTS APVRPTSTTK PMPAPTSQTP RQGVEHEASR DEEPRLTGGA
   301  AGHQDRSNSG QYPAKGGPQQ PHNKGCVAPT AGLAALLLAV AAGVLL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against LYPD3 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 0
Mean surface accessibility (rSASA): 0.45
Highest tissue expression: 1,071 nTPM

Expression across tissuesHPA

Tissue

esophagus: 1,071 nTPM
skin: 661 nTPM
vagina: 484 nTPM
cervix: 348 nTPM
salivary gland: 171 nTPM
tonsil: 124 nTPM

Single-cell type

esophageal apical cells: 6,604 nCPM
esophageal suprabasal cells: 4,474 nCPM
suprabasal keratinocytes: 2,733 nCPM
ocular epithelial cells: 1,242 nCPM
esophageal basal cells: 1,138 nCPM
syncytiotrophoblasts: 1,119 nCPM

Immune cell

naive CD4 T-cell: 5.5 nTPM
naive CD8 T-cell: 4.7 nTPM
memory CD4 T-cell: 2.9 nTPM
myeloid DC: 2.6 nTPM
neutrophil: 2.1 nTPM
total PBMC: 1.2 nTPM

Brain region

choroid plexus: 2 nTPM
hypothalamus: 1 nTPM
basal ganglia: 0.7 nTPM
medulla oblongata: 0.6 nTPM
midbrain: 0.6 nTPM
cerebral cortex: 0.5 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.91
gnomAD pLI: 0
gnomAD missense Z: 0.08
DepMap mean gene effect: -0.11
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

laminin binding

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of LYPD3 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads LYPD3 as an antibody target. Whether an autoantibody or antibody against LYPD3 could matter depends on whether native LYPD3 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

LYPD3 is annotated at the cell surface, where native LYPD3 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label LYPD3 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...